The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The purpose of the study is to determine whether oral semaglutide leads to greater weight loss compared with the placebo when combined with diet and exercise. Participants will take the assigned tablet every day for several months, attend regular clinic visits where their weight, waist size, blood pressure, and blood tests are checked, and report any side effects. The study will track changes in body weight and related health measures over the course of the trial.

The purpose of the study is to determine whether ALKS 2680 can reduce daytime sleepiness in adults with Narcolepsy Type 1. Participants will be randomly assigned to receive either the study drug or a placebo for about twelve weeks. During the study, they will complete a questionnaire called the Epworth Sleepiness Scale that asks how likely they are to fall asleep in everyday situations, and they will take a short test called the Maintenance of Wakefulness Test that measures how long they can stay awake when asked to do so. Their episodes of cataplexy will also be recorded each week.

Throughout the trial, researchers will monitor participants for any side effects and will collect the questionnaire and test results to evaluate the safety and effectiveness of the medication. The collected information will help decide if the drug provides a beneficial option for managing the symptoms of this sleep disorder.

The purpose is to find out whether adding this hormone support increases the chance of a baby being born alive compared with taking no active medication. Participants are randomly assigned to receive either the hormone capsule or the placebo for up to six months while trying to become pregnant naturally. Pregnancy outcomes, any side effects, and quality of life are recorded, and participants are followed for up to 18 months after the start of the study.

After the surgery, each person receives the assigned injection—either under the skin (subcutaneous) or into a muscle (intramuscular)—on a schedule set by the study team. Follow‑up visits are planned regularly to check health, monitor any side effects, and assess overall well‑being.

During the study, doctors will watch for any adverse events (unwanted health problems) and ask participants to complete questionnaires about their quality of life and daily functioning. This information helps determine if the treatment is safe and if it improves outcomes compared with the control injection.

The purpose of the study is to compare how long patients stay free of disease progression when venetoclax is continued for a longer period versus stopping after the initial six‑month course. After the six cycles of the combination, participants are randomly assigned—by chance—to either keep taking venetoclax for up to about 20 cycles or to stop the drug. All participants are then monitored with regular doctor visits, blood tests, and scans to check for any return of disease or side effects. The main outcome measured is progression free survival, which counts the time from random assignment until the disease gets worse or the patient dies.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

The main aim of the trial is to assess whether the drug improves daytime alertness in participants with this condition. Volunteers will be randomly assigned to receive either the active medication or the inactive comparator, and they will take the assigned tablet each day for approximately twelve weeks. Throughout the study period, participants will attend regular visits where simple questionnaires and brief safety checks will be performed to monitor how they feel and to ensure the treatment is well tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

The purpose of the study is to evaluate PFS at 12 months compared with historical results. After the first infusion, patients return for regular treatment sessions over several months while doctors monitor the cancer for any signs of growth or spread, record any side effects that are related to the immune system, and assess overall well‑being. PFS means the length of time a person lives without the disease getting worse. Immune‑related side effects are reactions that happen because the treatment activates the body’s own defenses, and quality of life refers to how a person feels and functions during the study.

People in the study are assigned by chance to receive either RO7795068 or placebo, and neither the participants nor the study team know which one is being given. The study lasts for about 72 weeks. During this time, the treatment is given regularly, and the study team checks body weight, general health, and possible side effects. The study also looks at changes in waist size, blood sugar, blood fats, blood pressure, eating habits, and quality of life.

Possible side effects, changes in blood tests, heart tracing results, and other safety checks are monitored throughout the study. The trial is designed to find out whether RO7795068 can help with weight management in adults with obesity or overweight who do not have type 2 diabetes.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

Participants in the study may receive MK-2870 through an intravenous infusion, which is a method of delivering medicine directly into a vein. Other participants will receive a choice of different chemotherapy drugs selected by the doctor, such as docetaxel, vinflunine, or paclitaxel. Some participants may also be given colony stimulating factors, which are substances used to help the body produce more white blood cells, or corticosteroids, which are medicines used to reduce swelling or inflammation.

Participants in this study will receive different combinations of medications as part of their adjuvant therapy, which is treatment given after the main treatment to lower the risk of the cancer returning. Some individuals will receive pembrolizumab along with capecitabine or olaparib. Other participants may receive tegafur, gimeracil, and oteracil. These medications are administered either through an intravenous infusion, which is medicine delivered directly into a vein, or by taking pills at home.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

The purpose of this study is to find out whether the study medications are better than placebo at reducing the occurrence of major liver-related complications. During the study, researchers will monitor participants for various liver problems including progression to cirrhosis (severe liver scarring), development of complications like varices (enlarged veins in the digestive tract), ascites (fluid buildup in the abdomen), hepatic encephalopathy (brain function problems caused by liver disease), and other serious liver conditions. The study will also track whether participants need liver transplantation or experience other serious outcomes.

Participants in this study will receive their assigned treatment over an extended period while being regularly monitored by the study team. The study requires participants to have evidence of liver fat confirmed by MRI (a type of imaging scan) and liver scarring confirmed through non-invasive tests, though a liver biopsy is not required to join the study. Throughout the study, participants will have regular check-ups and assessments to evaluate how well the treatment is working and to monitor their liver health and overall wellbeing.

Participants in the study will receive either the HLX10 treatment or a placebo, alongside the standard chemotherapy and radiotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the HLX10 or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with regular monitoring to assess the treatment’s impact on the cancer and any side effects experienced by the participants.

The main goal is to see if the combination of HLX10 with chemotherapy and radiotherapy can improve overall survival rates for patients with LS-SCLC. Secondary goals include measuring progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and the objective response rate, which is the proportion of patients whose cancer shrinks or disappears after treatment. The study will also monitor the quality of life of participants and any adverse events that occur during the trial.

The purpose of the study is to compare the effectiveness of these treatment combinations in patients with advanced NSCLC who have previously been treated with other therapies. Participants will be randomly assigned to one of the three treatment groups. The treatments will be given as an infusion, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period to assess how well the treatments work and to observe any side effects.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of the treatment. The study aims to provide valuable information on the potential benefits and risks of these treatment combinations for people with advanced Non-Small Cell Lung Cancer.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

The main goal of the study is to see how well each medicine cleans the bowel by measuring the cleanliness using a scoring system called the Boston Bowel Preparation Scale. The study will also look at how well children can follow the instructions for taking the medicine, how easy it is to drink, how it tastes, and whether children experience any unwanted effects from the medicine. Participants will be randomly assigned to receive either PLENVU or sodium picosulfate, meaning it will be decided by chance which medicine they get, similar to flipping a coin. The doctor performing the colonoscopy will not know which medicine the child received, which helps make the comparison fair.

During the study, children will take the bowel cleansing medicine at home before coming to the hospital or clinic for their colonoscopy. They or their parents will keep track of how much of the medicine they were able to drink and answer questions about how they felt while taking it. The colonoscopy will be performed as planned, and the doctor will score how clean the bowel is. After the colonoscopy, there will be a follow-up period to check on the child’s safety and well-being. The study is expected to start enrolling participants in early 2026 and finish in early 2027.

The purpose of the study is to see if trontinemab can slow down the worsening of symptoms in people with early Alzheimer’s Disease over a period of 72 weeks. During the study, people will receive either trontinemab or placebo through an infusion into a vein. The imaging substances will be given as injections to take special brain scans that show protein deposits linked to Alzheimer’s Disease. These scans help doctors understand what is happening in the brain.

Throughout the study, doctors will check how well people can think, remember things, and carry out everyday tasks using various tests and questionnaires. They will also monitor safety by checking for side effects, doing physical examinations, taking blood samples, and performing brain scans to look for any changes or problems. Some people in the study will have additional tests, including spinal fluid collection to measure certain proteins and extra brain scans to see tau protein, which is another substance that builds up in Alzheimer’s Disease. The study will measure changes in symptoms, brain protein levels, and overall safety of the treatment.

The study will last for 24 weeks, which is about six months. During this time, people in the study will be checked to see how their thinking abilities, daily activities, and overall condition change. The study will measure changes in memory and thinking using specific tests, and will look at how well people can perform everyday tasks. Doctors will also watch for any unwanted effects that might happen while people are taking the study medicine.

This is a type of study where neither the people taking part nor the doctors know who is getting the real medicine and who is getting placebo until the study is finished. This helps make sure the results are accurate and fair. The study will compare how people do on MK-1167 plus their usual medicine compared to people on placebo plus their usual medicine.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

Participants in this study will have been diagnosed with Parkinson’s Disease and will already be taking medication for their condition for at least three months. The study will look at whether prasinezumab can delay the time it takes for movement problems to get worse. Prasinezumab will be given through an intravenous infusion, which means it will be delivered directly into a vein. The study will measure various aspects of how participants move and function, including detailed assessments of motor function, which refers to how well a person can control their body movements.

During the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. This includes checking for infusion-related reactions, which are responses that can happen when medication is given through a vein. Regular health checks will be performed, including measurements of vital signs such as blood pressure and heart rate, blood tests, and assessments of overall wellbeing. The study will also track changes in the amount of Parkinson’s Disease medication that participants need to take over time, as well as how participants feel about changes in their condition.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The purpose of this study is to find out if the FOLFOXIRI treatment leads to better results in making the cancer disappear completely compared to the CAPOX or FOLFOX treatment in patients with high risk locally advanced rectal cancer. After completing the chemotherapy and chemoradiotherapy, patients will have imaging scans and examinations to check how well the cancer has responded to treatment. Depending on how the cancer responds, patients may either have surgery to remove the cancer or may be able to avoid surgery and be closely monitored instead, which is called a watch and wait approach.

During the study, patients will first receive several cycles of chemotherapy given through infusion into a vein over a period of weeks. This will be followed by chemoradiotherapy where radiation is given along with chemotherapy. After treatment is completed, doctors will use imaging tests and examinations to check if the cancer has disappeared or shrunk. The study will follow patients for several years to track whether the cancer comes back, whether patients are able to keep their rectum without surgery, and how the treatments affect their quality of life and ability to work. The study will also carefully monitor any side effects from the treatments and record any complications that may occur.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The purpose of the study is to find out if the spine block method is effective in reducing pain for patients with kidney stones, and whether it can improve patient satisfaction and reduce the need for hospital stays or additional procedures. The study will also look at whether this treatment can lower the amount of additional pain medication needed and reduce side effects from pain medications. After the initial treatment in the emergency department, patients will be asked about their pain levels at different times over the first 24 hours, and then again at seven days and one month later. The study will measure pain intensity, how much the pain interferes with daily activities, quality of life, and whether patients need to return to the emergency department or require surgery for their kidney stones.

During the study, patients will complete questionnaires about their pain, how it affects their daily activities, their overall well-being, and their satisfaction with the treatment. The study will track whether patients need to be admitted to the hospital, whether they require procedures to remove or break up the stones, and how much additional pain medication they use. The study will also monitor for any complications related to the treatment and will assess whether patients develop ongoing pain problems one month after receiving the treatment. Information about healthcare costs and time away from work will also be collected to understand the overall impact of the treatment.

The purpose of this study is to find out if JNJ-78278343 combined with usual care can help people live longer compared to placebo combined with usual care. The medication works by redirecting certain immune cells in the body to target a specific protein found on prostate cancer cells. People joining this study will have already tried several other treatments for their cancer, including hormone therapies, chemotherapy drugs called taxanes, and possibly other specialized treatments depending on what was available to them and what their doctors recommended.

During the study, participants will receive either the study medication or placebo through an infusion into their vein. They will continue their hormone therapy throughout the treatment period. The study will monitor how long participants live and track their overall health. People in the study should have cancer that has spread to bones or lymph nodes but not to major organs like the liver or lungs. They need to be well enough to carry out daily activities with some limitations but not be completely confined to bed or a chair.

The study will include adults between 40 and 80 years old who have moderate to severe lung disease with frequent flare-ups, meaning they have had at least two moderate flare-ups or one severe flare-up in the past year. Participants need to have higher levels of certain white blood cells called eosinophils in their blood. They should already be using three types of inhaled medications for their lung condition, including an inhaled steroid, for at least six months before joining the study. The study will look at how often flare-ups happen during treatment and will measure this over time.

During the study, participants will receive injections of either the study medication or placebo for up to 104 weeks. The study will measure how many flare-ups occur, how long it takes until the first flare-up happens, and how the disease affects daily life and breathing symptoms. Doctors will also track how many flare-ups require emergency room visits or hospital stays. Throughout the study, participants will continue taking their regular inhaled medications as prescribed by their doctor.

The purpose of the study is to compare how long people live without their cancer getting worse when they take casdatifan with cabozantinib compared to when they take placebo with cabozantinib. During the study, patients will take their assigned treatment for up to 120 months. The study will check how well the treatment works by using imaging scans to see if the tumors have grown, shrunk, or stayed the same size. These scans will be reviewed by independent experts who are not directly involved in treating the patients.

The study will also look at other important outcomes, including how long people live overall, how many people see their tumors shrink, how long the tumor response lasts, and how many people have their disease stay under control for at least 16 weeks. The study team will carefully monitor any side effects that occur and will track changes in symptoms related to the kidney cancer using questionnaires that ask about disease-related symptoms. Treatment can continue for up to 10 years, and the study is expected to be completed by mid-2029.

The purpose of this study is to evaluate the long-term safety and how well GSK4527226 works in people with early Alzheimer’s Disease. This is an extension study, which means it follows people who have already completed a previous study with the same medication. The study will look at any side effects that occur and will pay special attention to certain brain-related imaging findings that can sometimes happen with this type of treatment. These findings are monitored using brain scans to ensure participant safety throughout the study.

Participants will continue receiving GSK4527226 for up to 104 weeks, which is about two years. During this time, they will attend regular clinic visits where doctors will check their health and monitor for any unwanted effects. The study will also measure changes in memory, thinking abilities, and daily functioning using various assessments and questionnaires. A study partner, such as a family member or close friend who spends regular time with the participant, will need to attend some visits to provide information about how the participant is managing daily activities. All participants in this study will receive the active medication, as this is not a comparison study with placebo.

The purpose of this study is to evaluate how well acasunlimab works against tumors when given alone and when given together with pembrolizumab. The study will also look at the safety of these treatments. The main way the study will measure how well the treatments work is by checking how many people have their tumors shrink or disappear after receiving the treatment. This will be done using imaging scans that are evaluated according to standard criteria for measuring tumor response.

During the study, participants will receive their assigned treatment through infusions into a vein. The treatment may continue for up to 36 months depending on how well it works and how well it is tolerated. Throughout the study, doctors will regularly monitor participants with physical examinations, blood tests, and imaging scans to check how the cancer is responding to treatment and to watch for any side effects. The study is expected to begin enrolling participants in late 2025 and continue until mid-2029.

The study will involve people with mild to moderate Alzheimer’s Disease, who will receive either the study medications or placebo for 24 weeks. The medications are being tested to see if they can help improve cognitive function (thinking abilities) and daily functioning in people with Alzheimer’s Disease.

During the study, participants will take the medication daily and attend regular check-ups where their mental abilities and overall condition will be assessed. The study will track any changes in participants’ ability to think, perform daily activities, and their overall health status. Healthcare providers will monitor participants’ safety throughout the study period.

The main purpose of this research is to evaluate how well patients respond to treatment over an 18-month period. The study specifically targets newly diagnosed patients who have not received any previous treatment and are considered frail according to medical assessment criteria. Patients will be divided into two groups – one receiving daratumumab with teclistamab, and the other receiving daratumumab with talquetamab.

During the study, patients will receive their assigned combination of medications through injections under the skin. The treatment will continue while monitoring how well the cancer responds and checking for any side effects. The medications work by helping the body’s immune system fight against the cancer cells. Regular medical check-ups and tests will be performed to track the progress of the treatment.

The purpose of this research is to determine if using these clot-dissolving medications leads to better recovery in stroke patients who are already taking blood-thinning medicines. The medications will be compared to standard care treatment to see if they can improve patients’ ability to perform daily activities after their stroke.

During the study, participants will receive either one of the clot-dissolving medications or standard care treatment. The treatment must be given within 4.5 hours of when stroke symptoms begin. Doctors will monitor patients’ recovery and check for any bleeding complications. Follow-up assessments will be conducted over 90 days to evaluate how well patients recover from their stroke.

During the study, participants will receive either MK-2214 through intravenous infusion (delivery of medication through a vein) or a placebo. Additionally, participants will undergo PET scans (a type of medical imaging) using a substance called Florquinitau F18, which helps doctors see certain changes in the brain related to Alzheimer’s disease.

The study will monitor how the disease progresses over time by measuring changes in brain imaging and performing various tests that assess memory, thinking abilities, and daily living activities. The research team will also track any side effects that participants may experience during the treatment period, which may last up to 100 weeks.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The study will last 8 weeks and will test different doses of ALKS 2680. During the study, participants will receive either ALKS 2680 tablets or matching placebo tablets. The medication doses being tested range from 10 to 18 milligrams per day. The study is designed as a double-blind trial, which means neither the participants nor the doctors conducting the study will know who receives which treatment.

The effectiveness of the treatment will be measured by tracking changes in sleepiness levels using standardized assessment tools. Throughout the study, participants’ health and safety will be closely monitored through various medical checks. The study will also look at how well participants tolerate the medication and any effects it may have on their daily functioning.